35 employees
Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.
2010
$1M
from 1 investors over 1 rounds
Cantargia AB raised $1M on July 5, 2013
Investors: Sunstone Life Science Ventures